TP53 and pulmonary arterial hypertension: A recent study utilizing in vitro and animal models found that a Pol I inhibitor resulted in partial reversal of pulmonary arterial hypertension, prevention of perivascular inflammation, and activation of the tumor suppressor p53 [79].